There is significant research interest in developing and validating novel pancreatic cyst-fluid biomarkers given the increasing recognition of the prevalence of pancreatic cysts and their associated malignant potential. Although current international consensus guidelines are helpful, they fail to diagnose with certainty the cyst type and the level of epithelial dysplasia. They also fall short in predicting the future likelihood of malignant transformation. A systematic review was performed with the objective of summarizing cyst-fluid-based biomarkers that have been published in the medical literature over the past 10 years and characterizing the current quality of evidence. Our review demonstrates that there is an increasing interest in this topic with several different and innovative approaches including DNA, RNA, proteomic, and metabolomics profiling. Further techniques to improve upon cytological yield have also been studied. Besides identifying potentially useful clinical biomarkers, these empiric approaches have provided further insight into their pathogenesis. The level of evidence for the vast majority of these studies, however, is limited to retrospective early validation studies. The path forward will be to select out the most promising biomarkers and develop multicenter consortiums capable of capturing adequate sample sizes with appropriate study designs.
INTRODUCTION
Pancreatic cystic lesions are more frequently being identified with routine cross-sectional imaging. Although the exact prevalence in the general population is unknown, the best estimate is~2% for adults over the age of 40.
1,2 The incidence increases with age with~10% of patients over 80 having an incidental pancreatic cyst. The most commonly observed cyst types include intraductal papillary mucinous neoplasms (IPMN), mucinous cystic neoplasms (MCN), serous cystic neoplasms (SCN), and pseudocysts (PC). 3 MCNs and IPMNs harbor malignant potential and therefore require an accurate diagnosis with appropriate management. SCNs and PCs have no malignant potential and are subsequently managed differently.
International consensus guidelines were first developed in 2006 and recently updated in 2012 to standardize clinical management. 4, 5 These guidelines utilize the available evidence of clinical and imaging characteristics to recommend surgery or surveillance. In the 2006 criteria, surgery was recommended for all clinically suspected MCNs and main duct IPMNs. For cysts suspected of being a branch-duct IPMN, surgery was recommended if they had any of the following: (1) an intracystic mural nodule; (2) an associated dilated main duct; (3) a cyst size 43 cm; (4) associated clinical symptoms; or (5) positive cytology by endoscopic ultrasound (EUS) guided fine needle aspiration (FNA) . Although this algorithm demonstrated 100% sensitivity in identifying cysts with malignancy it had very-low specificity (23-31%) leading to many operations of questionable benefit. [6] [7] [8] The revised 2012 guidelines intended to increase the specificity without compromising sensitivity for malignancy. Criteria to proceed directly to surgery were narrowed to those with (1) obstructive jaundice, (2) an enhancing solid component associated with the cyst, and (3) a main duct dilated 410 mm. These differences are highlighted in Table 1 . For those with worrisome features, but none of the above high-risk stigmata, EUS is recommended to triage patients for surgery or surveillance.
Although these guidelines are helpful, they exist because there is currently no accurate and reliable method to obtain a definitive diagnosis. The preoperative diagnosis for cyst type is incorrect in 20-30% of cases. 9, 10 Imaging modalities including computed tomography and magnetic resonance imaging are also suboptimal with poor interobserver variability. 11, 12 Among the imaging modalities, EUS is considered the most sensitive in delineating malignant characteristics such as mural nodules. [13] [14] [15] [16] [17] [18] [19] [20] [21] With EUS, FNA of the cyst can be performed for cytology. Because of the low amount of epithelial cells in the cyst fluid however, cytology has had a limited diagnostic yield with a pooled sensitivity of 63% and specificity of 88%.
Specifically, a low value does not rule out a mucinous cyst and often surveillance is still required. [23] [24] [25] The most recent consensus guideline recommends CEA be used in limited settings "in whom additional information will have an impact on the surgical decision making." 14 Given this limit in diagnostic accuracy with current imaging modalities, there remains a growing research interest in discovering and validating novel cyst-fluid biomarkers that may improve upon the performance of CEA. The types of biomarkers available for analysis have been expanding rapidly due to the development of innovative technologies that enable profiling of various bioparticles in the cyst fluid.
In this review, we attempt to comprehensively describe and categorize the published pancreatic cyst-fluid biomarkers. In doing so, we describe the current level of evidence for each biomarker in the context of a proposed framework for further validation to bring it into clinical practice. 26 
METHODS
This systematic review was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Eligible articles were identified by search of the MEDLINE database for the past 10 years (1 February 2005 to 1 February 2015). The following keywords were used: "pancrea*" AND "cyst*" AND "biomarker", "pancrea*" AND "cyst*" AND "diagnosis", "intraductal papillary mucinous neoplasm" AND ("RNA", OR "DNA", OR "protein" OR "proteomics" OR "cytokine" OR "metabolomics"), "mucinous cystic neoplasm" AND ("RNA", OR "DNA", OR "protein" OR "proteomics" OR "cytokine" OR "metabolomics"), "serous cystadenoma" AND ("RNA", OR "DNA", OR "protein" OR "proteomics" OR "cytokine" OR "metabolomics") and "pseudocyst" AND ("RNA", OR "DNA", OR "protein" OR "proteomics" OR "cytokine" OR "metabolomics").
Reported biomarkers based on immunohistochemistry or those not obtained directly from the pancreatic cyst by FNA were excluded (this includes studies of duodenal fluid). Studies that used cyst fluid obtained at surgery were included as there does not appear to be a difference with cyst fluid obtained during EUS. 27 Studies only in English using human samples were included. Only studies that used histology as the gold standard were included. Review articles were excluded. As CEA is already used in current practice, further validation studies of CEA were excluded. The references of retrieved relevant reviews and articles were reviewed to identify other potential eligible studies. Both authors reviewed eligible studies from the search results. Data abstraction included the following variables: publication year, study design, sample size, distribution of cyst types, presence of histologic correlation, primary comparison (e.g., mucinous vs. non-mucinous, cancer vs. non-cancer, and serous cystadenoma vs. non-serous cystadenoma), area under the receiver operator curve (ROC), sensitivity, specificity, and diagnostic accuracy.
RESULTS
A total of 2,840 articles were screened. Of these, 203 articles were further assessed for eligibility, and 41 studies were included in this review. Reasons for exclusion include: CEA validation studies (n = 21), Immunohistochemistry only studies (n = 45), pancreatic juice studies (n = 13), review articles (n = 12), and not meeting other inclusion/exclusion criteria (n = 71).
DNA-based biomarkers. One of the first DNA-based biomarker studies in cyst-fluid was of KRAS mutations, which are present in over 90% of pancreatic adenocarcinomas and represent the most frequent and earliest genetic alterations toward cancer. 28 Khalid et al. 29 first described a potential difference in cyst-fluid expression using 36 samples that included 11 malignant cysts and 15 premalignant cysts. Besides studying KRAS mutations, DNA quantity, quality, number and sequence of mutations were also studied. Several subsequent studies followed using these set of DNA parameters (Table 1) . [30] [31] [32] [33] [34] [35] [36] [37] In sum, these studies showed the presence of a KRAS mutation to be highly specific (80-100%) but limited in sensitivity (33-86%) for diagnosing mucinous cysts (IPMN or MCN). More importantly, the majority of these studies did not find KRAS to be useful for differentiating malignant from premalignant mucinous cysts. However, in combination with other DNA parameters such as allelic loss, a few studies demonstrated decent sensitivity and specificity for diagnosing malignant cysts. Its routine use, consequently, remains controversial and is not widely accepted.
In search of other relevant mutations that might provide insight into the pathogenesis of IPMNs, Wu et al. 38 performed an exploratory DNA analysis of cyst fluid from 19 patients with IPMNs. They identified recurrent mutations in codon 201 of GNAS (guanine nucleotide-binding protein G subunit alpha isoforms short) that is highly specific for IPMNs. Using a larger cohort of 147 cyst-fluid samples, they observed that 61% of IPMNs had GNAS mutations compared to 0% in SCNs and MCNs. Subsequent studies have since been performed on cyst fluid that validate these earlier findings (Table 2) . 39, 40 Although these studies were relatively smaller in sample size, they reproduced the observation that GNAS mutations were found only in IPMNs, (but not all IPMNs) and that the presence of either a GNAS or KRAS mutation was highly sensitive for IPMNs. The increasing use of next-generation sequencing technology may further elucidate other clinically useful DNA mutations to aid in the diagnosis and management of premalignant and malignant IPMNs and MCNs. 41 Specifically, DNA mutations that are specific for high-risk cystic lesions (i.e., high-grade dysplasia and/or cancer) are yet to be identified. RNA-based biomarkers. There were five studies investigating micro-RNA (miRNA) biomarkers from cyst fluid (Table 3) . [42] [43] [44] [45] [46] Compared with DNA-based studies, this research studies have all been recently published in the last 4 years. While, the majority of these studies were primarily exploratory in nature without an a priori hypothesis, the fundamental basis for investigating miRNA stems from earlier observations that they can be involved in tumor initiation and progression. 47 Two of the studies identified miRNA 21 to have clinical utility. Ryu et al. 44 showed that miRNA 21 could differentiate mucinous cysts from non-mucinous cysts. Farrell et al. 43 also observed that miRNA 21 could differentiate premalignant mucinous cysts from malignant cysts. Other studies identified a panel of miRNAs, and miRNA 216 and 217 as potentially useful for diagnosing surgically recommended cysts. 42, 46 These studies suggest that miRNA bear significant potential to become useful clinical tests with further validation.
Exploratory proteomic approaches. Like differential expressions observed in DNA and RNA profiles observed between cancer and normal tissue, differential protein expression may be logical focus for diagnostic test development. Several exploratory studies looking for differential protein expression in pancreatic cyst fluid have been performed (Table 4) . [48] [49] [50] [51] [52] [53] [54] [55] Like the RNA-based cyst studies, these did not have an a priori target and used technical variations of mass spectrometry. The sample sizes were generally small ranging from 8 to 59 samples, and the majority of them reported select protein groups that were differentially expressed in clinically relevant cyst types. For example, Allen et al. 49 used a commercially available luminex assay and found a cluster of 14 proteins that differentiated SCNs from IPMNs with 92% accuracy. Although these empirical studies provide indirect insight into the pathogenesis of the various relevant cyst types and may identify candidate targets for further study, translation of these immediate findings into an easily usable diagnostic or predictive test remains a challenge.
Targeted protein-based biomarkers. Twelve studies were identified that reported on a specific protein or group of proteins in an exploratory or validation study for being potentially useful as a cyst-fluid biomarker (Table 5) . [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] Not surprisingly, a commonly studied protein group in cyst-fluid biomarkers is the secreted mucin proteins. Glycan variants on certain mucin proteins such as MUC5AC, have been described to be particularly sensitive (87-89%) and specific (80-100%) for diagnosing mucinous cysts. 57, 66 Maker et al. 65 found certain mucin proteins (MUC2 and MUC4) could differentiate dysplasia status in IPMNs. MorrisStiff et al. 64 studied general mucin expression by direct staining of the cyst fluid and observed a sensitivity of 80% and specificity of 40% for diagnosing mucinous cysts. Cao et al. 66 also studied glycan alterations on mucin proteins and found that a three-marker panel could differentiate mucinous from non-mucinous cysts with high diagnostic accuracy. Of the different subtypes of mucin proteins, aberrant MUC1 has been strongly associated with pancreatic cancer. Jabbar et al. 59 targeted MUC1 and observed it to diagnose malignant Among the other studies, there are a few that appear to be promising and worth further validation primarily because of their potential to directly impact surgical decision-making. Maker et al. 61 looked at cytokine expression differences and observed that IL-1B, an important pro-inflammatory mediator, was significantly higher in IPMNs with high-grade dysplasia and malignancy than low grade IPMNs (ROC 0.92). Amphiregulin, a secreted epidermal growth factor receptor ligand that is overexpressed in pancreatic cancer, has also been shown to differentiate high-grade dysplastic and cancerous cysts with an ROC of 0.76. 58, 68 Raty et al. 67 observed that cyst-fluid SPINK1 levels in pancreatic cysts could differentiate surgically recommended lesions (MCN, and main/mixed IPMNs) with an ROC of 0.94. More recently, Das et al. 62 reported on the clinical utility of a monoclonal antibody reactive against a colonic phenotype of epithelium in pancreatic cysts. Monoclonal antibody Das-1 could differentiate high-risk IPMNs that might require surgery from low-risk IPMNs. This particular analysis was unique in that definition of high-risk incorporated IPMN histological subtype. The majority of these biomarkers focuses on identifying which lesions are high risk and necessitate immediate surgery. In contrast, Yip-Schneider et al. 63 showed that cyst-fluid VEGF could diagnose SCNs with an ROC40.99. Such a biomarker would remain valuable as these cysts do not need require surgery or need to be followed.
Metabolomics. If DNA profiling explains "what can happen", RNA profiling explains "what appears to be happening", and protein profiling explains "what makes it happen", then metabolite profiling explains "what has happened and is happening". 69 To date, there is one study that profiles metabolites in the cyst fluid (Table 6 ). Park et al. used a semi-targeted method and identified four metabolites that were differentially expressed in mucinous cysts compared to non-mucinous cysts. With mass spectrometry, two were identified as glucose and kynurenine. The latter is a tryptophan metabolite that has been associated with cancer development. 70 With a sample size of 45 cysts, both glucose (ROC 0.92) and kynurenine (0.94) demonstrated high diagnostic accuracies for mucinous cysts. 71 Cytology revisited. One of the major impetuses for identifying novel cyst-fluid biomarkers stems from the poor diagnostic accuracy of cyst-fluid cytology. For the diagnosis of high-grade dysplasia or cancer, the specificity is high, while the sensitivity is low making it of limited value for surgical decision-making. 72 This has been attributed to the scant quantity and quality of aspirated cells from the cyst cavity. To make cytological-based analysis more clinically useful, Pitman et al. devised a modified cytological system that included a category of atypical epithelial cells (AEC). AECs were defined by the presence of a single or cluster of cells with a relatively increased nuclear to cytoplasmic ratio and enlarged irregular nuclei. With this new classification system, they showed that in a sample of 18 patients, 83% (5 out of 6) of those with high-grade dysplasia or higher had the presence of AECS compared to 33% (4 out of 12) that did not. 73 Using a larger sample cohort of 112 patients with mucinous cysts (39 of which were malignant), AEC sensitivity was 72% and specificity was 85% for diagnosing malignant cysts (Table 6) . 74 While this is significantly improved from the standard cytological classification system, its generalizability remains a significant barrier as substantial experience is required to achieve fair agreement among pathologists. were 11 studies within our inclusion and exclusion criteria. In the latter half, there were 30 studies. This does not include numerous studies that were based on immunohistochemistry expression. The vast majority of the studies included in this review were single center retrospective studies and required histology as the gold standard for comparison. This latter part includes a selection bias that may limit the generalizability of these studies. Specifically, these sample cohorts select for a higher proportion of high-risk cystic lesions, which will likely impact the diagnostic performance characteristics in routine clinical settings when the majority of lesions tested will be lowrisk cysts. A framework for advancing biomarkers from the laboratory to the bedside has been proposed. 26 This proposed pathway for the discovery and validation of cancer biomarkers has five phases: preclinical exploratory (phase 1), clinical assay and validation (phase 2), retrospective longitudinal (phase 3), prospective screening (phase 4), and cancer control (phase 5). (Figure 1 ) Preclinical exploratory studies typically compare tumor tissue from nontumor tissue to look for difference in tumor markers or gene expression levels. A clinical assay uses non-invasive methods to obtain specimens from cases as well as control subjects or subjects with benign growths to estimate the sensitivity and specificity to evaluate if biomarkers can be used for screening purposes. The third phase is a retrospective longitudinal study with aims to understand as a function of time before clinical diagnosis, the capacity of the biomarker to detect preclinical disease and identify the criteria for a positive screening test. The fourth phase is a prospective study where the diagnostic test is applied to individuals, with a standardized protocol for definitive treatment (i.e., surgery) to those testing positive. The final phase is a population-based cancer control study, which investigates whether testing reduces the burden of cancer on the population. Not all phases are required to bring biomarkers to clinical use but at least successful performance in a phase 3 study is required for validation.
In the context of this framework, the studies described in this review are in phases 1 or 2 (listed in Tables 2-6 ). The next steps for new cyst-fluid biomarkers to enter clinical practice will be to complete phase 2 validation studies for those that have only undergone phase 1 and begin planning a phase 3 studies of the most promising biomarkers. Phase 3 studies will be based on repositories from centers that have already been banking pancreatic cyst fluid. These samples will be collected only by EUS that in the future (but not immediately) will have undergone surgery. The goal will be to assess the biomarker's capacity to predict disease and will be assessed retrospectively. Sample sizes with adequate power will need to be collated and will require a multicenter collaboration. With proper design and application, retrospective longitudinal studies can allow for rapid clinical uptake of novel biomarkers. Successful phase 3 studies should be enough to enable implementation into clinical practice. These studies should include minimally acceptable true-and false-positive rates for testing defined by community consensus. Based on what is known of the indolent nature for most of these premalignant cysts, phase 4 prospective studies, while important, will require a very large sample with longitudinal follow-up that may not be practical or feasible to define as the threshold prior to introduction into clinical practice.
In conclusion, there are several promising cyst-fluid biomarkers in the literature that warrant a concerted coordinated multicenter effort. Among those discussed, the most promising include KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog), GNAS, miRNA 21, and glucose to differentiate nonmucinous from mucinous cyst types. MUC1, amphiregulin, IL-1B, SPINK1, mAb Das-1, and miRNA 21 should be further studied to differentiate low-risk from high-risk cyst types (those harboring high-grade dysplasia, or invasive cancer). VEGF should be further validated for its ability to diagnose serous cystic neoplasms. Phase 3 retrospective longitudinal study designs represent the next rational step forward. As this will require significant pooling of resources, careful consideration in the planning stages should be made to allow the most number of potential biomarkers to be studied, both alone and in combination with each other. This will also ensure that we reach our shared goal of bringing new diagnostic tests and improving the management of patients with pancreatic cysts.
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